Li, P., Shan, J., Chen, X., Zhang, D., Su, L., Huang, X., Yu, B., Zhi, Q., Li, C., Wang, Y., Tomei,  

S., Cai, Q., Ji, J., Li, J., Chouchane, L., Yu, Y., Sun, F., Xu, Z., Liu, B. and Zhu, Z., 2015.  

Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin  

E2/interleukin-6 signaling in the tumor microenvironment. Cell Research, 25(5), pp.588-603.  

Liu, Q., Cai, J., Zheng, Y., Tan, Y., Wang, Y., Zhang, Z., Zheng, C., Zhao, Y., Liu, C., An, Y.,  

Jiang, C., Shi, L., Kang, C. and Liu, Y., 2019. NanoRNP Overcomes Tumor Heterogeneity in  

Cancer Treatment. NANO LETTERS, 19(11), pp.7662-7672.  

Liu, Q., Zhao, K., Wang, C., Zhang, Z., Zheng, C., Zhao, Y., Zheng, Y., Liu, C., An, Y., Shi, L.,  

Kang, C. and Liu, Y., 2018. Multistage Delivery Nanoparticle Facilitates Efficient  

CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo. Advanced Science, 6(1),  

p.1801423.  

Xiong, G., Liu, C., Yang, G., Feng, M., Xu, J., Zhao, F., You, L., Zhou, L., Zheng, L., Hu, Y.,  

Wang, X., Zhang, T. and Zhao, Y., 2019. Long noncoding RNA GSTM3TV2 upregulates LAT2  

and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic  

cancer. Journal of Hematology & Oncology, 12(1).  

Li X, Li J, Cai Y, et al. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Letters. 2018 Apr 1; 418: 211-20.

Shi C, Ren L, Sun C, et al. miR-29a/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients. British Journal of Cancer. 2017 Sep 26; 117: 1036-47.

Xu W, Zhang Z, Zou K, et al. MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. Cell death & disease. 2017 May 4; 8: e2761.

Zhou Z, Wan J, Hou X, et al. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy. Cell death & disease. 2017 Mar; 8(3): e2658.

Zhuang L, Wang X, Wang Z, et al. MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/β-catenin signaling by targeting ST7L in hepatocellular carcinoma. Cell Death & Disease. 2017 May 18; 8: e2804.

Sun H J, Zhao M X, Liu T Y, et al. Salusin-βinduces foam cell formation and monocyte adhesion in human vascular smooth muscle cells via miR155/NOX2/NFκB pathway. Scientific Reports. 2016 Mar 23.

Wang Z, Li H, Guo R, et al. Antioxidants inhibit advanced glycosylation end-product-induced apoptosis by downregulation of miR-233 in human adipose tissue-derived stem cells. Scientific Reports. 2016 Mar 11.

Zhang Y, Zhou S Y, Yan H Z, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting surviving and Bmi-1. Scientific Reports. 2016 Feb 5.

Gao S, Tian H, Guo Y, et al. miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. Acta Biomaterialia. 2015 Oct; 25:184-93. 

Li P, Shan J X, Chen X H, et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell research. 2015; 25(5): 588-603.

Liu F, Kong X, Lv L, et al. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial–mesenchymal transition and cancer stem cell phenotypes. Cancer Letters. 2015 Apr 10; 359(2):288-98. 

Liu X, Lei Q, Yu Z, et al. MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget. 2015 Feb 11; 6(10): 7930-43.

Liu Y, Song Z M, Deng X, et al. Chitosan-coated red fluorescent protein nanoparticle as a potential dual-functional siRNA carrier. Nanomedicine. 2015 Jul; 10(13): 2005-16.

Ren R J, Zhang Y F, Dammer E B, et al. Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism. Molecular Neurobiology. 2015 Oct 26.

Tan Y, Yin H, Zhang H, et al. Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer. Oncotarget. 2015 Mar 25; 6(19): 17391-403.